ArticleFrontiers in neurology2023
Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study.
Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03814226 (The Effect of PACAP-38 Infusion in Inducing Headache in Patients With Cluster Headache), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of PACAP-38 Infusion in Inducing Headache in Patients With Cluster Headache
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Hallmarks of primary headache: part 3 - cluster headache.The journal of headache and pain · 2025Review
- Targeting PACAP: Beyond Migraine to Cluster, Menstrual, and Post-traumatic Headaches.Advances in therapy · 2025Review
- Unraveling the relationship between inflammation and cluster headache.Frontiers in neurology · 2025Review
- Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders.Annals of clinical and translational neurology · 2024Review
- Cluster headache: understandings of current knowledge and directions for whole process management.Frontiers in neurology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether infusions of PACAP and VIP caused alterations in plasma levels of VIP and their potential contribution to induced cluster headache attacks. Methods: Participants received either PACAP or VIP infusion for 20 min on 2 separate days with an interval of at least 7 days in between. Blood collection was performed at T Results: Blood samples were collected from participants with episodic cluster headache in the active phase (eCHA, Conclusion: Cluster headache attacks induced by PACAP38 or VIP infusion are not associated with changes in plasma levels of VIP. Further studies are needed to investigate the role of VIP and the parasympathetic system in cluster headache. Clinical trial registration: The parent study is registered at ClinicalTrials.gov (NCT03814226).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.